MONROVIA, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, the only company to make a human milk fortifier (HMF) from human milk, as opposed to cow milk, for critically ill premature infants in the neonatal intensive care unit, has named Sally Crawford to their board of directors.
Sally Crawford has a stellar reputation in the healthcare industry, with experience that spans over 30 years. For over 10 years she served as COO of Healthsource, Inc., a publicly traded NYSE HMO and managed care company. She has also served as a health care consultant to industry leaders such as Bayer HealthCare. Ms. Crawford serves as a member of the board of directors for several healthcare organizations, including Hologic, Inc., EXACT Sciences, Inc., Zalicus Inc., Universal American and Insulet Corporation.
Prolacta’s primary product, Prolact+ H2MF®, is the only HMF made from 100% human milk, and is prescribed by neonatologists for infants weighing 2 pounds 12 ounces or less at birth. Prolact+ H2MF can only be used in a hospital setting and cannot be purchased directly by consumers. In order to increase the protein and other caloric needs of the preemie, Prolact+ H2MF is added to the mother’s breast milk, or to donor milk if a mother’s own milk is unavailable. This feeding solution has proven to have several clinical benefits, and provides an exclusively human milk diet for the fragile infant.
About Prolacta Bioscience
Prolacta Bioscience, Inc. www.prolacta.com is a life science company dedicated to improving quality of life by Advancing the Science of Human Milk™. Prolacta creates specialty formulations made exclusively from human milk for the nutritional needs of critically ill, premature infants in neonatal intensive care units. It is the first and only company to provide a human milk fortifier made from 100% human milk, Prolact+ H2MF. They operate a pharmaceutical grade processing plant and have designed and patented processes that enable them to make their one-of-a-kind life saving products. Prolacta is committed to making a meaningful difference in the lives of the most vulnerable infants through world-class research and innovative products.